Compare HRMY & ANDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | ANDE |
|---|---|---|
| Founded | 2017 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2020 | 2005 |
| Metric | HRMY | ANDE |
|---|---|---|
| Price | $37.03 | $67.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $44.11 | ★ $75.00 |
| AVG Volume (30 Days) | ★ 854.1K | 319.7K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | 7.97 | ★ 12.93 |
| EPS | 0.55 | ★ 0.97 |
| Revenue | $868,453,000.00 | ★ $11,008,928,000.00 |
| Revenue This Year | $19.75 | $7.28 |
| Revenue Next Year | $12.88 | $3.57 |
| P/E Ratio | ★ $67.75 | $68.35 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $31.84 |
| 52 Week High | $40.87 | $82.11 |
| Indicator | HRMY | ANDE |
|---|---|---|
| Relative Strength Index (RSI) | 68.61 | 39.22 |
| Support Level | $35.05 | $66.03 |
| Resistance Level | $39.12 | $74.24 |
| Average True Range (ATR) | 1.04 | 2.00 |
| MACD | 0.22 | -0.38 |
| Stochastic Oscillator | 93.53 | 25.00 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Andersons Inc is an agriculture and renewable fuels company. Its operations are classified into two reportable business segments: Agribusiness, which generates maximum revenue, and Renewables. The Agribusiness segment includes merchandising and managing logistics across various commodities, as well as being a manufacturer, distributor, and retailer of agricultural and related plant nutrients. The segment specializes in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. The Renewables segment mainly produces, purchases, and sells ethanol and co-products. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.